BMW i Ventures, Dell Technologies Capital and Robert Bosch Venture Capital are in line to exit the manufactiuring services marketplace, which has filed for a $100m offering.

Noria Therapeutics and PSMA Therapeutics have both been acquired by Bayer, which will integrate their respective assets into its own oncology portfolio.

IP Group sold a $5m stake to incoming shareholder Celltrion as part of a series A round for Iksuda, a spinout of Bath originally called Glythera.

The Johnson & Johnson, GlaxoSmithKline and DaVita HealthCare Partners-backed medical device producer is looking to raise $75m in an offering on the Nasdaq Global Market.

HubSpot has exited the marketing platform developer in an acquisition by Attentive that follows some $8m of funding.

The e-commerce software provider has been acquired by CDK Global after approximately $24m in funding from investors including Liberty Mutual.

Sham Innovation Santé is set to exit the oncology diagnostics test developer in an cash-and-stock acquisition expected to close later this year.

Qualcomm Ventures and Samsung Ventures are in line for exits as the cybersecurity technology provider - valued at $3bn as of November - looks to float.

Lumar is set to exit the Gen Z-focused social commerce platform in an acquisition by Etsy that comes after about $100m in funding.

WuXi AppTec, Fosun, Sinopharm and Humanwell have all invested in the oncology treatment developer, which has filed to raise up to $100m.